2021
DOI: 10.1016/s2468-1253(20)30304-6
|View full text |Cite
|
Sign up to set email alerts
|

Anal cancer and precancerous lesions: a call for improvement

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
29
0
2

Year Published

2021
2021
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 25 publications
(31 citation statements)
references
References 70 publications
0
29
0
2
Order By: Relevance
“…Furthermore, anal Papanicolaou (Pap) screening for the precancerous HPV anal lesions as a secondary prevention may have greater utility in preventing future anal cancer [28][29][30][31] and indeed is a cost-effective method for anal cancer prevention among MSM [32,33]. Anal cancer screening could follow a very similar process to that for cervical cancer screening, however, with an exclusive focus on high-risk groups [34].…”
Section: Introductionmentioning
confidence: 99%
“…Furthermore, anal Papanicolaou (Pap) screening for the precancerous HPV anal lesions as a secondary prevention may have greater utility in preventing future anal cancer [28][29][30][31] and indeed is a cost-effective method for anal cancer prevention among MSM [32,33]. Anal cancer screening could follow a very similar process to that for cervical cancer screening, however, with an exclusive focus on high-risk groups [34].…”
Section: Introductionmentioning
confidence: 99%
“…As per NIH guidelines, annual DAREs are recommended for individuals who are HIV positive. 10 However, even in developed countries, performance of a DARE is lacking. Farooq et al demonstrated that 46.2% of the patients referred for the confirmed diagnosis of rectal cancer, did not recall having a DARE by their primary care provider, despite having anorectal symptoms or a positive fecal immunochemical test.…”
Section: Existing Screening/surveillance Approachesmentioning
confidence: 99%
“…25 However, colonoscopic evaluation does not detect distal anal canal and perianal intraepithelial lesions. 10 Anoscopy, HRA, and endoscopy present the opportunity for therapeutic intervention of dysplastic pathology.…”
Section: Existing Screening/surveillance Approachesmentioning
confidence: 99%
See 1 more Smart Citation
“…The reported incidence of anal cancer in general population is 1.8 per 100,000 persons [ 12 ], in MSM it ranges between 19–35 cases per 100,000 and up to 88–131/100,000 in MSM living with HIV, i.e., more than 70 times more common than in the general population [ 9 , 13 15 ]. The increasing incidence of anal cancer can be associated with increases in the number of sexual partners and a higher prevalence of anal sex in the past few decades [ 16 , 17 ].…”
Section: Introductionmentioning
confidence: 99%